» Articles » PMID: 33846957

A Psychometric Evaluation of the Functional Assessment of Cancer Therapy-kidney Symptom Index (FKSI-19) Among Renal Cell Carcinoma Patients Suggesting an Alternative Two-factor Structure

Overview
Journal Qual Life Res
Date 2021 Apr 13
PMID 33846957
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To psychometrically evaluate the hypothesized four-factor structure of the 19-item Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI-19) health-related quality of life (HRQoL) instrument in a sample of surgically treated renal cell carcinoma (RCC) patients and examine if an alternative factor structure with good psychometric properties may be derived from the available items.

Methods: The model fit of the hypothesized four-factor structure was examined using confirmatory factor analysis on cohort data from 1731 individuals included in the National Swedish Kidney Cancer Register who had undergone surgery for RCC during the three years 2016-2018 and answered the FKSI-19 instrument within 6-12 months after surgery. Exploratory factor analysis was applied to the same dataset to derive a possible alternative factor solution.

Results: The four-factor structure did not reach the thresholds for good model fit using the normed χ-value or the Comparative Fit Index, although the Standardized Root Mean Square Residual and Root Mean Square Error of Approximation measures indicated good and acceptable model fits, respectively. An alternative 14-item trimmed FKSI version (FKSI-14) with a two-factor structure derived from the available FKSI-19 items was found to measure the same aspects of HRQoL as the full FKSI-19 instrument.

Conclusion: The present study is the first to use psychometric methods for examining the factor structure of the FKSI-19 instrument. The hypothesized four-factor structure of FKSI-19 provided a barely acceptable model fit. The two-factor FKSI-14 structure may be used as an alternative or complement to the four-factor structure when interpreting the FKSI-19 instrument.

Citing Articles

Reply to Letter to the Editor about "Recurrences after nephron-sparing treatments of renal cell carcinoma: a competing risk analysis" by Qiang et al.

Karlsson Rosenblad A, Mazin Hashim B, Lindblad P, Ljungberg B World J Urol. 2024; 42(1):621.

PMID: 39495377 DOI: 10.1007/s00345-024-05304-7.


Recurrences after nephron-sparing treatments of renal cell carcinoma: a competing risk analysis.

Karlsson Rosenblad A, Mazin Hashim B, Lindblad P, Ljungberg B World J Urol. 2024; 42(1):474.

PMID: 39112814 PMC: 11306276. DOI: 10.1007/s00345-024-05172-1.


The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214.

Cella D, Choueiri T, Hamilton M, Blum S, Ivanescu C, Karu K Oncologist. 2024; 29(6):511-518.

PMID: 38280218 PMC: 11144972. DOI: 10.1093/oncolo/oyae003.


Patients' Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19.

Bergerot C, Malhotra J, Bergerot P, Philip E, Castro D, Hsu J Oncologist. 2023; 28(6):494-500.

PMID: 36917626 PMC: 10243758. DOI: 10.1093/oncolo/oyad028.


A Systematic Review of Heterogeneity in Outcome Definition and Reporting in Localised Renal Cancer.

Beyer K, Widdershoven C, Wintner L, Dabestani S, Marconi L, Moss C Eur Urol Open Sci. 2022; 48:1-11.

PMID: 36578462 PMC: 9791121. DOI: 10.1016/j.euros.2022.11.014.

References
1.
Ludvigsson J, Otterblad-Olausson P, Pettersson B, Ekbom A . The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009; 24(11):659-67. PMC: 2773709. DOI: 10.1007/s10654-009-9350-y. View

2.
Cella D, Yount S, Du H, Dhanda R, Gondek K, Langefeld K . Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). J Support Oncol. 2006; 4(4):191-9. View

3.
Hsieh J, Purdue M, Signoretti S, Swanton C, Albiges L, Schmidinger M . Renal cell carcinoma. Nat Rev Dis Primers. 2017; 3:17009. PMC: 5936048. DOI: 10.1038/nrdp.2017.9. View

4.
Thorstenson A, Bergman M, Scherman-Plogell A, Hosseinnia S, Ljungberg B, Adolfsson J . Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005-2010: a population-based study from the national Swedish kidney cancer register. Scand J Urol. 2014; 48(3):231-8. DOI: 10.3109/21681805.2013.864698. View

5.
Cella D, Yount S, Brucker P, Du H, Bukowski R, Vogelzang N . Development and validation of a scale to measure disease-related symptoms of kidney cancer. Value Health. 2007; 10(4):285-93. DOI: 10.1111/j.1524-4733.2007.00183.x. View